By Professor Michael Leonard Friedlander

Conference Papers

Deva S; Lee J-S; Lin C-C; Yen C-J; Millward M; Chao Y; Keam B; Jameson M; Hou M-M; Kang Y-K; Markman B; Lu C-H; Rau K-M; Lee K-H; Horvath L; Friedlander M; Hill A; Wu J; Hou J; Desai J, 2018, 'A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SWITZERLAND, Geneva, presented at ESMO Immuno-Oncology Congress, SWITZERLAND, Geneva, 13 December 2018 - 16 December 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000459294800077&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sandhu S; Hill A; Gan H; Friedlander M; Voskoboynik M; Barlow P; Townsend A; Song J; Zhang Y; Liang L; Desai J, 2018, 'Tislelizumab, an anti-PD-1 antibody, in patients with urothelial carcinoma (UC): Results from an ongoing phase I/II study', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SWITZERLAND, Geneva, pp. 28 - 28, presented at ESMO Immuno-Oncology Congress, SWITZERLAND, Geneva, 13 December 2018 - 16 December 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000459294800083&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Goh JC; Baron-Hay S; Bonaventura T; Buck M; Dean A; Friedlander M; Gao B; Mileshkin L; Oehler MK; Steer C; Vi N; Goble S; Grechko N; Monk BJ; Kristeleit RS, 2018, 'ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled, phase 3 study of rucaparib plus nivolumab following front-line platinum-based chemotherapy in ovarian cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 196 - 196, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000449544200343&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Moore KN; Colombo N; Scambia G; Kim B-G; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza AM; Gonzalez-Martin A; Aghajanian C; Bradley W; Lowe ES; Bloomfield R; DiSilvestro P, 2018, 'Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, GERMANY, Munich, pp. 727 - 727, presented at 43rd ESMO Congress (ESMO), GERMANY, Munich, 19 October 2018 - 23 October 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000459277305017&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Antill Y; Barlow-Stewart K; Friedlander M; Meiser B; Do J; Nevin S; Gleeson M; Kentwell M; Tucker K; Taylor N; Kirk J, 2018, 'Changing a nation: The development and evaluation of a training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients.', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, BMJ PUBLISHING GROUP, pp. 202 - 203, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000471153100137&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza AM; González-Martín A; Aghajanian C; Bradley W; Lowe ES; Bloomfield R; DiSilvestro P, 2018, 'Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial', in Annals of oncology : official journal of the European Society for Medical Oncology, pp. viii727, http://dx.doi.org/10.1093/annonc/mdy424.041

Mileshkin L; Sivakumaran T; Grant P; Na L; Friedlander M; Webb P; Au-Yeung G, 2018, 'COMPARING THE IMPACT OF DOSE REDUCTIONS/ DELAYS ON OVARIAN CANCER OUTCOMES USING THREE WEEKLY OR DOSE DENSE CARBOPLATIN/ PACLITAXEL REGIMENS IN THE NATIONAL PROSPECTIVE OPAL COHORT', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, BMJ PUBLISHING GROUP, pp. 770 - 770, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000471152401334&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Webb PM; Beesley V; deFazio A; Obermair A; Grant PT; Nagle C; Friedlander M, 2018, 'The hidden burden of anxiety and depression in ovarian cancer: A prospective study from diagnosis.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2018 - 05 June 2018, http://dx.doi.org/10.1200/JCO.2018.36.7_suppl.155

Webb PM; deFazio A; Obermair A; Grant PT; Friedlander M; Beesley V; Nagle C, 2018, 'The Ovarian cancer Prognosis And Lifestyle (OPAL) study.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2018 - 05 June 2018, http://dx.doi.org/10.1200/JCO.2018.36.7_suppl.88

Webb PM; Beesley V; Nagle C; Grant PT; deFazio A; Obermair A; Friedlander M, 2018, 'When will I feel normal again? Quality of life trajectories after first-line chemotherapy for ovarian cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2018 - 05 June 2018, http://dx.doi.org/10.1200/JCO.2018.36.7_suppl.172

Sackeyfio A; Nussey F; Friedlander M; Pujade-Lauraine E, 2018, 'Comparative efficacy and tolerability of the PARP inhibitors, olaparib 300 mg tablets BID, niraparib 300 mg capsules QD and rucaparib 600 mg tablets BID as maintenance treatment in BRCA-mutated (BRCAm) platinum-sensitive relapsed ovarian', in GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS INC ELSEVIER SCIENCE, pp. 43 - 44, http://dx.doi.org/10.1016/j.ygyno.2018.04.094

Vergote I; Hanker LC; Floquet A; Rau J; Kim J-W; Izquierdo EO; Friedlander M; Pignata S; Fujiwara K; Colombo N; Mirza MR; Monk BJ; Moertl M; Calvert P; Herzog TJ; Jackisch C; Meunier J; Lee J-Y; Belau AK; Du Bois A, 2018, 'AGO-OVAR 16: A phase III study to evaluate the efficacy and safety of pazopanib (PZ) monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer-Overall survival (OS) results', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.5518

Friedlander M; Chan JK; Java J; Armstrong DK; Markman M; Herzog TJ; Monk BJ; Backes FJ; Secord AA; Bonebrake AJ; Rose PG; Tewari KS; Mannel RS; Lentz SS; Geller MA; Copeland LJ, 2018, 'Characterization and predictors of long term (>= 10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer patients.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.5556

Sivakumaran T; Mileshkin LR; Grant PT; Friedlander M; Webb PM; Au-Yeung G, 2018, 'Comparing the impact of dose reductions and delays on ovarian cancer patient outcomes with three-weekly versus dose dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.5568

Friedlander M; King M; Nagle C; Obermair A; Grant PT; deFazio A; Webb PM, 2018, 'Getting the most out of follow-up: A prospective study using the Measure of Ovarian Symptoms and Treatment concerns (MOST) symptom index to evaluate and track adverse effects (AEs) and detect symptoms of recurrence in patients with ovarian cancer (OC) following first line chemotherapy (1LT).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.10062

Wilson MK; Chawla T; Wang L; Friedlander M; Oza AM; Lheureux S, 2018, 'Inter and intra-observer variability with the assessment of RECIST in ovarian cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.5555

Banerjee SN; Tang M; O'Connell R; Clamp AR; Lord R; Mullassery VM; Hall M; Gourley C; Bonaventura T; Goh JC; Sykes P; Grant PT; McNally O; Edmondson RJ; Friedlander M, 2018, 'PARAGON: A phase 2 study of anastrozole (An) in patients with estrogen receptor(ER) and / progesterone receptor (PR) positive recurrent/metastatic granulosa cell tumors/sex-cord stromal tumors (GCT) of the ovary', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.5524

Sjoquist KM; Mileshkin LR; Ananda S; Shannon CM; Bowtell D; Yip S; Espinoza D; Goh JC; Harrison ML; Plebanski M; Gebski V; Stockler MR; Livingstone K; Tang M; Friedlander M, 2018, 'REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal (IP) bevacizumab (bev) for recurrent ascites in advanced, chemotherapy-resistant, epithelial ovarian cancer (CR-EOC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.10097

Webb PM; Beesley V; deFazio A; Obermair A; Grant PT; Nagle CM; Friedlander M, 2018, 'The hidden burden of anxiety and depression in ovarian cancer: A prospective longitudinal study from diagnosis.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.10081

Nayar N; Lawrence NJ; Stockler MR; Martin AJ; Yip S; Wong N; Yeung A; Friedlander M; Mazhar D; Pashankar F; Quinn DI; McDermott R; Walker R; Winstanley M; Hanning FJ; Weickhardt AJ; Stevanovic AG; Davis ID; Toner GC; Grimison PS, 2018, 'P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poorrisk metastatic germ cell tumors (GCTs).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, CA, San Francisco, presented at Genitourinary Cancers Symposium, CA, San Francisco, 08 February 2018 - 10 February 2018, http://dx.doi.org/10.1200/JCO.2018.36.6_suppl.TPS574

Sandhu SK; Hill AG; Gan HK; Friedlander M; Voskoboynik M; Barlow P; Townsend AR; Song J; Zhang Y; Shen Z; Qi Q; Desai J, 2018, 'Preliminary results from patients with urothelial carcinoma (UC) in a phase 1A/1B study of bgb-A317, an anti-PD-1 monoclonal antibody.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, CA, San Francisco, presented at Genitourinary Cancers Symposium, CA, San Francisco, 08 February 2018 - 10 February 2018, http://dx.doi.org/10.1200/JCO.2018.36.6_suppl.445

Friedlander M; Meniawy T; Markman B; Mileshkin LR; Harnett P; Millward M; Lundy J; Freimund AE; Norris C; Wu J; Paton V; Wang L; Gao B, 2018, 'A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, CA, San Francisco, 25 January 2018 - 27 January 2018, http://dx.doi.org/10.1200/JCO.2018.36.5_suppl.48

Wong N; Nayar N; Lawrence N; Stockler M; Martin A; Yip S; Yeung A; Friedlander M; Mazhar D; Pashankar F; Quinn D; Walker R; Winstanley M; Weickhardt A; Hanning F; Stevanovic A; Davis I; Toner G; Grimison P, 2017, 'P3BEP (ANZUP 1302): An International Randomised Phase III Trial of Accelerated Versus Standard BEP Chemotherapy for Adult and Pediatric Male and Female Patients With Intermediate and Poor-Risk Metastatic Germ Cell Tumours (GCTS)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 168 - 168, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413954500265&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Penson R; Kaminsky-Forrett M-C; Ledermann J; Brown C; Plante M; Korach J; Huzarski T; Lista AGDL; Pisano C; Friedlander M; Colombo N; Gropp-Meier M; Nakai H; Sonke GS; Kim J-W; Vergote I; Allen A; Pujade-Lauraine E, 2017, 'Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: Phase III SOLO2 trial (ENGOT Ov-21)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Madrid, presented at 42nd European-Society-for-Medical-Oncology Congress (ESMO), SPAIN, Madrid, 08 September 2017 - 12 September 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000411324002120&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ritchie G; Gasper H; Man J; Lord S; Friedlander M; Lee C; Marschner I, 2017, 'is objective response rate (ORR) a valid primary endpoint in phase 2 trials (Ph2t) of immune checkpoint inhibitors (ICI) for advanced solid cancers?', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Madrid, presented at 42nd European-Society-for-Medical-Oncology Congress (ESMO), SPAIN, Madrid, 08 September 2017 - 12 September 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000411324003027&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Meniawy T; Richardson G; Townsend A; Desai J; Gan H; Friedlander M; Horvath L; Jameson MB; Sandhu S; Wu Z; Qin Z; Kang K; Markman B, 2017, 'Preliminary results from a subset of patients (pts) with advanced ovarian cancer (OC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Madrid, presented at 42nd European-Society-for-Medical-Oncology Congress (ESMO), SPAIN, Madrid, 08 September 2017 - 12 September 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000411324001049&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Peate M; Jayasinghe Y; Allingham C; Hucker A; Kemertzis M; Meiser B; Friedlander M; Hickey M, 2017, 'Supporting fertility decision-making: the role of decision aids in oncofertility.', in PSYCHO-ONCOLOGY, WILEY, pp. 166 - 166, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000407688900459&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Friedlander M; Pujade-Lauraine E; Ledermann JA; Penson RT; Oza AM; Korach J; Huzarski T; Poveda A; Pignata S; Colombo N, 2017, 'Treatment with Maintenance Olaparib Significantly Improves Progression-Free Survival in Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Results of SOLO2 Study', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 51 - 51, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000427542700014&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Desai J; Gan H; Barrow C; Jameson MB; Solomon B; Atkinson V; Haydon A; Millward M; Begbie S; Brown M; Markman B; Patterson W; Hill A; Horvath L; Nagrial A; Richardson G; Jackson C; Friedlander M; Gibbs D; Parente P; Yang J; Wang L; Chen Y; Luo L, 2017, 'Abstract CT002: A Phase IB study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors', in Cancer Research, American Association for Cancer Research (AACR), pp. CT002 - CT002, http://dx.doi.org/10.1158/1538-7445.am2017-ct002

Rohr I; Hilpert V; Heitz F; Fehm T; Canzler U; Friedlander M, 2017, 'Symptom burden and outcomes in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive ROC receiving ≥3 lines of chemotherapy (PPS ≥3) – The Gynecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS)', in Geburtshilfe und Frauenheilkunde, Georg Thieme Verlag KG, presented at Jahrestagung der Österreichischen Gesellschaft für Gynäkologie und Geburtshilfe (OEGGG) gemeinsam mit der Bayerischen Gesellschaft für Geburtshilfe und Frauenheilkunde e.V (BGGF), 14 June 2017 - 17 June 2017, http://dx.doi.org/10.1055/s-0037-1602307

Friedlander M; Meniawy T; Markman B; Mileshkin LR; Harnett PR; Millward M; Lundy J; Freimund AE; Norris C; Mu S; Wu J; Paton VE; Wang L; Gao B, 2017, 'A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.3013

Friedlander M; Gebski V; Gibbs E; Bloomfield R; Hilpert F; Wenzel LB; Joly F; Eek D; Rodrigues M; Clamp AR; Penson RT; Provencher DM; Korach J; Huzarski T; Vidal L; Salutari V; Scott CL; Nicoletto MO; Tamura K; Pujade-Lauraine E, 2017, 'Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.5507

Ledermann JA; Embleton AC; Perren T; Jayson GC; Rustin GJS; Kaye SB; Hirte HW; Oza AM; Vaughan MM; Friedlander M; Martin AG; Clark E; Popoola B; Farrelly L; Swart AM; Cook A; Kaplan RS; Parmar MKB, 2017, 'Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.5506

Grimison PS; Lawrence NJ; Stockier MR; Martin AJ; Yip S; Wong N; Yeung A; Friedlander M; Mazhar D; Pashankar F; Quinn DI; Walker R; Winstanley M; Nanning FJ; Weickhardt AJ; Stevanovic AG; Davis ID; Toner GC, 2017, 'P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.TPS4592

Roncolato F; Joly F; O'Connell R; Lanceley A; Heitz F; Buizen L; Okamoto A; Aotani E; Salutari V; Donnellan PP; Oza AM; AvalI-Lundqvist E; Berek JS; Hilpert F; Feeney A; Roemer-Becuwe C; Stockier MR; King MT; Friedlander M, 2017, 'Predictors of stopping chemotherapy early and short survival in patients with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) who have had >= 3 lines of prior chemotherapy: The GCIG symptom benefit study (SBS).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.5575

Heinzelmann-Schwarz VA; Russell K; Omar S; Schoetzau A; Hoeck K; Vetter M; Fink DA; Friedlander M; Hacker NF, 2017, 'Should MMMT of the endometrium/ovary be treated with anthracycline instead of taxane based chemotherapy?', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.5563

Piskorz A; Lin KK; Morris J; Mann E; Oza A; Coleman RL; O'Malley DM; Friedlander M; Cragun JM; Ma L; Giordano H; Rosenfeld N; Raponi M; McNeish IA; Swisher E; Brenton JD, 2017, 'Abstract AP27: FEASIBILITY OF MONITORING RESPONSE TO THE PARP INHIBITOR RUCAPARIB WITH TARGETED DEEP SEQUENCING OF CIRCULATING TUMOR DNA (CTDNA) IN WOMEN WITH HIGH GRADE OVARIAN CARCINOMA ON THE ARIEL2 TRIAL', in Clinical Cancer Research, American Association for Cancer Research (AACR), pp. AP27 - AP27, http://dx.doi.org/10.1158/1557-3265.ovcasymp16-ap27

Joly F; Hilpert F; Okamoto A; Stuart G; Ochiai K; Friedlander M, 2017, 'Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer', in European Journal of Cancer, pp. 133 - 138, http://dx.doi.org/10.1016/j.ejca.2017.03.019

Pujade-Lauraine E; Ledermann JA; Penson RT; Oza AM; Korach J; Huzarski T; Poveda A; Pignata S; Friedlander M; Colombo N, 2017, 'Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study', in GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS INC ELSEVIER SCIENCE, pp. 219 - 220, http://dx.doi.org/10.1016/j.ygyno.2017.03.505

Han HS; Dieras V; Robson ME; Palacova M; Marcom PK; Jager A; Bondarenko I; Citrin D; Campone M; Telli ML; Domchek SM; Friedlander M; Man BK; Ratajczak C; Coates A; Bonnet P; Qin Q; Qian J; Giranda VL; Shepherd SP; Isakoff SJ; Puhalla S, 2016, 'Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc) plus C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 06 December 2016 - 10 December 2016, http://dx.doi.org/10.1158/1538-7445.SABCS16-S2-05

Dieras V; Han HS; Robson ME; Palacova M; Marcom PK; Jager A; Bondarenko I; Citrin D; Campone M; Telli ML; Domchek SM; Friedlander M; Kaufman B; Ratajczak C; Coates A; Bonnet P; Qin Q; Qian J; Giranda VL; Shepherd SP; Puhalla S; Isakoff SJ, 2016, 'Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V plus TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc) plus C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 06 December 2016 - 10 December 2016, http://dx.doi.org/10.1158/1538-7445.SABCS16-P4-22-02

Piskorz AM; Lin KK; Morris J; Mann E; Oza A; Coleman RL; O'Malley DM; Friedlander M; Cragun JM; Ma L; Giordano H; Raponi M; McNeish IA; Swisher E; Brenton JD, 2016, 'Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high grade ovarian carcinoma on the ARIEL2 trial', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, GERMANY, Munich, pp. S123 - S123, presented at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, GERMANY, Munich, 29 November 2016 - 02 December 2016, http://dx.doi.org/10.1016/S0959-8049(16)32966-5

Hickey M; Sousa MS; Peate M; Jarvis S; Friedlander M, 2016, 'SHORT-TERM FINDINGS OF THE PEGASUS STUDY: GENITOURINARY SYMPTOMS, SEXUALITY AND QUALITY OF LIFE IN BREAST CANCER SURVIVORS ON ENDOCRINE THERAPY - WHAT ARE WE MISSING?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 71 - 71, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000387769900021&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mercieca-Bebber R; Calvert MJ; Kok P-S; Friedlander M; Kyte DG; Stockler M; King M, 2016, 'Does the patient-reported outcome (PRO) content of protocols impact PRO completion rates and the standard of reporting? A review of international ovarian cancer randomized controlled trials (RCTs)', in QUALITY OF LIFE RESEARCH, SPRINGER, pp. 119 - 119, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000398451600288&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Wenzel L; King M; Lee C; Kirby A; Friedlander M; Hilpert F; Stockler M; Gelski V, 2016, 'Relationship between distress and survival in women with platinum-resistant ovarian cancer (PROC)', in QUALITY OF LIFE RESEARCH, SPRINGER, pp. 125 - 125, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000398451600301&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lawrence N; Grimison P; Stockler M; Martin A; Buizen L; Thomson D; Gebski V; Friedlander M; Yeung A; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong S; Lewis C; Vasey P; Toner G, 2016, 'LONG-TERM OUTCOMES OF ACCELERATED BEP (BLEOMYCIN, ETOPOSIDE, CISPLATIN) FOR ADVANCED GERM CELL TUMORS: UPDATED ANALYSIS OF AN AUSTRALIAN MULTICENTER PHASE II TRIAL (3033)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 48 - 48, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000380005100014&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lawrence N; Martin A; Toner G; Stockler M; Buizen L; Thomson D; Gebski V; Friedlander M; Yeung A; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong S; Lewis C; Vasey P; Grimison P, 2016, 'LONG-TERM OUTCOMES OF ACCELERATED BEP (BLEOMYCIN, ETOPOSIDE, CISPLATIN) FOR ADVANCED GERM-CELL TUMORS: UPDATED ANALYSIS OF AN AUSTRALIAN MULTICENTER PHASE II TRIAL', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 28 - 28, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000380004900011&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Desai J; Markman B; Sandhu SK; Gan HK; Friedlander M; Tran B; Meniawy T; Boolell V; Colyer D; Norris C; Ameratunga M; Yang J; Li K; Wang L; Luo L; Qin Z; Millward M, 2016, 'A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.3066

Roncolato F; O'Connell R; Buizen L; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Pignata S; Donnellan PP; Oza AM; Avall-Lundqvist E; Berek JS; Sjoquist KM; Gillies K; Stockler MR; King MT; Friedlander M, 2016, 'Baseline quality of life (QOL) as a predictor of stopping chemotherapy early, and of overall survival, in platinum-resistant/refractory ovarian cancer (PRROC): The GCIG symptom benefit study (SBS).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.5508

Piskorz A; Lin KK; Morris JA; Mann E; Oza AM; Coleman RL; O'Malley DM; Friedlander M; Cragun JM; Ma L; Giordano H; Raponi M; McNeish IA; Swisher EM; Brenton JD, 2016, 'Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.5549

Back to profile page